Tobias Wrenfield

Transdermal delivery could reshape GLP-1 side effects by changing absorption kinetics.

Nose-to-brain peptide platforms need three structural advantages to overcome delivery barriers.

The physics of peptide size and skin chemistry make passive delivery impossible.

These drugs work far beyond blood sugar control across multiple organs.

Nanoparticles engineered to protect peptides through nasal passages and into the brain.

Intranasal delivery bypasses the blood-brain barrier through direct neural pathways in the nose.

Nanoparticles engineer a direct neural bypass for drugs blocked by the blood-brain barrier.

Researchers use incompatible tools to measure whether patients take their peptide medications.

Sublingual and buccal routes hit a permeability wall that formulation cannot solve.

Researchers engineer patches and energy methods to deliver large peptides through skin.

Injection achieves near-total absorption, but oral peptides barely survive the digestive gauntlet.

Weekly injections drive patients away faster than the drugs themselves work.

How the route into your body shapes which GLP-1 receptor populations the drug can reach.

The gut destroys ninety percent of oral semaglutide before it enters the bloodstream.

Diabetes drug shows promise in mice but fails to slow Parkinson's in humans.